Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial

Open access

Abstract

Rationale: Idiopathic pulmonary fibrosis (IPF) is a rare and progressive disease that causes progressive cough, exertional dyspnea, impaired quality of life, and death. Objectives: Bexotegrast (PLN-74809) is an oral, once-daily, investigational drug in development for the treatment of IPF. Methods: This Phase-2a multicenter, clinical trial randomized participants with IPF to receive, orally and once daily, bexotegrast at 40 mg, 80 mg, 160 mg, or 320 mg, or placebo, with or without background IPF therapy (pirfenidone or nintedanib), in an approximately 3:1 ratio in each bexotegrast dose cohort, for at least 12 weeks. The primary endpoint was incidence of treatment-emergent adverse events (TEAEs). Exploratory efficacy endpoints included change from baseline in FVC, quantitative lung fibrosis (QLF) extent (%), and changes from baseline in fibrosis-related biomarkers. Measurements and Main Results: Bexotegrast was well tolerated, with similar rates of TEAEs in the pooled bexotegrast and placebo groups (62/89 [69.7%] and 21/31 [67.7%], respectively). Diarrhea was the most common TEAE; most participants with diarrhea also received nintedanib. Participants who were treated with bexotegrast experienced a reduction in FVC decline over 12 weeks compared with those who received placebo, with or without background therapy. A dose-dependent antifibrotic effect of bexotegrast was observed with QLF imaging, and a decrease in fibrosis-associated biomarkers was observed with bexotegrast versus placebo. Conclusions: Bexotegrast demonstrated a favorable safety and tolerability profile, up to 12 weeks for the doses studied. Exploratory analyses suggest an antifibrotic effect according to FVC, QLF imaging, and circulating levels of fibrosis biomarkers. Clinical trial registered with www.clinicaltrials.gov (NCT04396756).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.202403-0636oc

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Study design. *One participant, randomized to placebo, received 320 mg bexotegrast for approximately 1 week because of incorrect study-drug dispensation. No adverse events were reported for this participant. They are included in the denominator of the placebo and 320-mg bexotegrast group for the safety analyses. This figure represents the intent-to-treat population. Y/N = yes/no.
Figure 1. Study design. *One participant, randomized to placebo, received 320 mg bexotegrast for approximately 1 week because of incorrect study-drug dispensation. No adverse events were reported for this participant. They are included in the denominator of the placebo and 320-mg bexotegrast group for the safety analyses. This figure represents the intent-to-treat population. Y/N = yes/no.CC BY-NC-ND · PubMed Central
Figure 2. Participant disposition. *Adverse event (n = 3), withdrawal of consent (n = 1), physician decision (n = 1). †Adverse event (n = 1), withdrawal of consent (n = 2), physician decision (n = 1). ‡Eighty-eight participants were randomized to receive bexotegrast; however, one participant, randomized to placebo, received both placebo and 320 mg bexotegrast for approximately 1 week because of incorrect study-drug dispensation. They are included in the denominator of the placebo and 320-mg bexotegrast groups for the safety analyses.
Figure 2. Participant disposition. *Adverse event (n = 3), withdrawal of consent (n = 1), physician decision (n = 1). †Adverse event (n = 1), withdrawal of consent (n = 2), physician decision (n = 1). ‡Eighty-eight participants were randomized to receive bexotegrast; however, one participant, randomized to placebo, received both placebo and 320 mg bexotegrast for approximately 1 week because of incorrect study-drug dispensation. They are included in the denominator of the placebo and 320-mg bexotegrast groups for the safety analyses.CC BY-NC-ND · PubMed Central
Figure 3. Change in FVC from baseline to Week 12 (efficacy for modified intent-to-treat population). (A–D) Change in FVC from baseline through Week 12 in all participants receiving (A) 40 mg, (B) 80 mg, (C) 160 mg, and (D) 320 mg bexotegrast compared with placebo. Change from baseline was analyzed using a mixed model for repeated measures. *P < 0.05 versus placebo. **P < 0.01 versus placebo. LS = least squares.
Figure 3. Change in FVC from baseline to Week 12 (efficacy for modified intent-to-treat population). (A–D) Change in FVC from baseline through Week 12 in all participants receiving (A) 40 mg, (B) 80 mg, (C) 160 mg, and (D) 320 mg bexotegrast compared with placebo. Change from baseline was analyzed using a mixed model for repeated measures. *P < 0.05 versus placebo. **P < 0.01 versus placebo. LS = least squares.CC BY-NC-ND · PubMed Central
Figure 4. Percentage of participants with FVC (A) relative decline ⩾10% of predicted and (B) absolute decline ⩾10% of predicted at Week 12 (efficacy for modified intent-to-treat population).
Figure 4. Percentage of participants with FVC (A) relative decline ⩾10% of predicted and (B) absolute decline ⩾10% of predicted at Week 12 (efficacy for modified intent-to-treat population).CC BY-NC-ND · PubMed Central
Figure 5. Exploratory endpoints. (A) Mean change in QLF (%) from baseline to Week 12. (B) Least squares (LS) mean change from baseline in plasma ITGB6 relative to placebo at Weeks 4 and 12. (C) LS mean change from baseline in serum PRO-C3 relative to placebo at Weeks 4 and 12. The data in (A) are per computed tomography protocol population (a subset of the intent-to-treat population with available high-resolution computer tomography imaging data and images) who completed the study without any major protocol violations within the prespecified time interval between screening and randomization. The data in (B) and (C) are from the pharmacodynamic analysis population. Change from baseline in biomarker concentration was analyzed using a mixed model for repeated measures. *P < 0.05 versus placebo. **P < 0.01 versus placebo. ****P < 0.0001 versus placebo. ITGB6 = integrin β-6; NPX = Normalized Protein eXpression; PRO-C3 = type III collagen synthesis neoepitope; QLF = quantitative lung fibrosis.
Figure 5. Exploratory endpoints. (A) Mean change in QLF (%) from baseline to Week 12. (B) Least squares (LS) mean change from baseline in plasma ITGB6 relative to placebo at Weeks 4 and 12. (C) LS mean change from baseline in serum PRO-C3 relative to placebo at Weeks 4 and 12. The data in (A) are per computed tomography protocol population (a subset of the intent-to-treat population with available high-resolution computer tomography imaging data and images) who completed the study without any major protocol violations within the prespecified time interval between screening and randomization. The data in (B) and (C) are from the pharmacodynamic analysis population. Change from baseline in biomarker concentration was analyzed using a mixed model for repeated measures. *P < 0.05 versus placebo. **P < 0.01 versus placebo. ****P < 0.0001 versus placebo. ITGB6 = integrin β-6; NPX = Normalized Protein eXpression; PRO-C3 = type III collagen synthesis neoepitope; QLF = quantitative lung fibrosis.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Research works printed but not linked: 5

  1. Wuyts, 2023, Late breaking abstract—Safety, tolerability and antifibrotic activity of bexotegrast: phase 2a. INTEGRIS-IPF study (NCT04396756), Eur Respir J, 62, OA1423
  2. Lancaster, 2023, PLN-74809 shows favorable safety and tolerability and indicates antifibrotic activity in a phase 2a study for the treatment of idiopathic pulmonary fibrosis, Am J Respir Crit Care Med, 207, A2777
  3. Cosgrove, 2022, PLN-74809, a dual-selective inhibitor of αvβ6 and αvβ1, is well tolerated in over 280 healthy participants, Am J Respir Crit Care Med, 205, A2437
  4. Mooney, 2022, PLN-74809, a dual-selective inhibitor of integrins αvβ6 and αvβ1, shows dose-dependent target engagement in the lungs of patients with idiopathic pulmonary fibrosis (IPF), Am J Respir Crit Care Med, 205, A5254
  5. Cosgrove, 2022, PLN-74809, an oral, dual-selective αvβ6/αvβ1 inhibitor in phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF), sustainably reduces transforming growth factor-beta (TGF-β) activity in the lungs of healthy participants with once-daily dosing, Am J Respir Crit Care Med, 205, A5251

Cited by

See all 93

Metadata

Authors
Lancaster, L., Cottin, V., Ramaswamy, M., Wuyts, W. A., Jenkins, R. G., Scholand, M. B., Kreuter, M., Valenzuela, C., Ryerson, C. J., Goldin, J., Kim, G. H. J., Jurek, M., Decaris, M., Clark, A., Turner, S., Barnes, C. N., Achneck, H. E., Cosgrove, G. P., Lefebvre, É. A., & Flaherty, K. R.
Affiliations
  • Vanderbilt University Medical Center (US)
  • Lyon 1 Université (FR)
  • Cone Health (US)
  • Universitair Ziekenhuis Leuven (BE)
  • National Heart and Lung Institute, Imperial College London, London, United Kingdom
  • University of Utah (US)
  • University Medical Center of the Johannes Gutenberg University Mainz (DE)
  • Hospital Universitario de La Princesa (ES)
  • University of British Columbia (CA)
  • University of California, Los Angeles (US)
  • Pliant (United States) (US)
  • Pliant Therapeutics, Inc., South San Francisco, California; and
  • University of Michigan (US)
Corresponding author
Lancaster, Lisa
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2024-08
Volume
210
Issue
4
Pages
424-434
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W4399393072
Cited by
80
References
46
Citations by year
2026: 35 · 2025: 37 · 2024: 8
FWCI
23.24
Type
journal article
Language
en
Open access
Locations
  • American Journal of Respiratory and Critical Care Medicine (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • Lirias (KU Leuven) (submittedVersion, cc-by-nc-nd)
Funders
Pliant Therapeutics
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Keywords
idiopathic pulmonary fibrosis, antifibrotic therapy, treatment-emergent adverse events, safety and tolerability, forced vital capacity decline, fibrosis biomarkers, pirfenidone, nintedanib, dose-dependent effects, diarrhea
MeSH terms
Aged, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Indoles, Male, Middle Aged, Pyridones, Treatment Outcome, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial. https://app.cochat.ai/papers/10.1164/rccm.202403-0636oc
The paper
Lancaster, L., Cottin, V., Ramaswamy, M., Wuyts, W. A., Jenkins, R. G., Scholand, M. B., Kreuter, M., Valenzuela, C., Ryerson, C. J., Goldin, J., Kim, G. H. J., Jurek, M., Decaris, M., Clark, A., Turner, S., Barnes, C. N., Achneck, H. E., Cosgrove, G. P., Lefebvre, É. A., & Flaherty, K. R. (2024). Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.202403-0636oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.